Smoking status and sex as indicators of differences in 2582 obese patients presenting for weight management
Vascular Health and Risk Management, 05/08/2012
Abunassar MJ et al. - Obese never smokers suffer from the fewest chronic diseases. Obese former smokers have a greater prevalence of coronary artery disease (CAD), type 2 diabetes (T2DM) on pharmacotherapy, and impaired fasting glucose than other groups. Thus, clinicians and researchers should avoid combining former smokers with never smokers as “nonsmokers” in research and treatment decisions. The results of this study call for a longitudinal study comparing these groups over the weight management program.
Between September 1992 and June 2007, 2582 consenting patients starting the Ottawa Hospital Weight Management program were grouped by sex and smoking status.
“Former smokers” (771 females, 312 males) had quit for at least 1 year.
There were 979 females and 331 males who never smoked.
Using SAS 9.2 statistical software, the prevalence of coronary artery disease (CAD), type 2 diabetes (T2DM), major depressive disorder (MDD), and medication use among the groups was compared (Chi-square [χ2]).
Anthropometric measurements, lipid, glucose and thyroid levels were compared using analysis of variance (ANOVA).
Interactions were assessed using 2-way ANOVA analysis for continuous data, and logistic regression for discrete data.
Smokers were more likely to have MDD (χ2), lower high-density lipoprotein levels and higher triglyceride levels than other groups.
Former smokers had a greater prevalence of CAD, T2DM on pharmacotherapy, and impaired fasting glucose than other groups.
They were also more likely to be taking lipid-lowering agents and antihypertensives (χ2).
Never smokers had less MDD, CAD, and were less likely to be on antidepressants than the other groups.
Males were more likely to have CAD and T2DM than females.
Females were more likely to have MDD than males.
Interactions between smoking status and sex were found for age, weight, fasting glucose and thyroid-stimulating hormone levels.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.